Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2000; 46(4): 80-87


Neuromediatory Mechanismsof Corazole Action

Kalueff A. V., Filonenko M. A., Gromov L. A

    *Centre for Physiology and Biochemical Research,Kiev, Moscow;**Institute of Pharmacology and Toxicology,Academy of Medical Science of Ukraine, Kiev


Abstract

Present paper analyses the known neurotropic effects of GABA-lytic agent corazole (pentylentetrazole), including both «traditional» anxiogenic convulsant properties at systemic doses > 10 mg/kg and reported recently its anxiolytic effects in doses < 2 mg/kg. Understanding the relations between anxiogenic and convulsant properties of a drug, we studied possible effects of pre-treatment by «anxiolytic» dose of corazole (1 mg/kg i.p.) on corazole-induced convulsions at systemic dose of 90 mg/kg in mice. Despite the expectations, small dose of corazole (1 mg/kg) did not reduce convulsions but rather increased them. This result challenges the hypothesis of possible GABA-ergic mechanisms of «positive» effects of corazole in small doses. The potentiation effects were particularly marked for Straube symptom. The symptom is believed to reflect the excitation of inhibitory spinal motoneurons responsible for tail muscles tonus. Perhaps, corazole at a systemic dose of 1 mg/kg can influence separately on the GABA-receptors located in spinal motoneurons or cells oforigin of supruspinal pathways. Other possible neuromediatory (including glycine-, glytamat-, opioid-, choline- and monoaminergic) mechanisms for corazole action are discussed to illustrate the mosaic of its neurotropic properties.

References

  1. Абрамец И.И. Типы серотониновых рецепторов, их функциональная роль и участие в действии психофармакологических средств // Фармакология и токсикология. —1990. — 53, № 5. — С. 70-75.
  2. Авакян Р.М. О роли стриатума во влиянии серотонинергических веществ на течениекоразоловых судорог у крыс // Бюл. эксперим. биологии и медицины. — 1976. —82, № 7. — С. 789-792.
  3. Биоскрининг. Лекарственные средства / Под ред. А.В.Стефанова. — К. : Авиценна,1998. — С.21-33.
  4. Веселкин Н.П., Аданина В.О., Рио Ж.П., Реперант Ж. Сосуществование нейро-трансмиттеров в синаптических окончаниях тормозных синапсов // Рос. физиол.журн. им. И.М.Сеченова. — 1999. — 85, № 4. — С. 515-522.
  5. Гацура В.В. Методы первичного фармакологического исследования биологическo активных веществ. — М.: Медицина, 1974. — 143 с.
  6. Громов Л.А. Нейропептиды. — К.: Здоров’я, 1992. — 247 с.
  7. Жила В.А., Гаценко Г.Н., Громов Л.А. Биохимический антагонизм холинолитиков ихолиномиметиков на уровне опиатной системы // Фармакология и токсикология.—1991. — 54, № 6.— С. 14-16.
  8. Ковтуненко В.О. Лікарські засоби з дією на центральну нервову систему. — К.:Перун, 1997. — 464 с.
  9. 9. Лаврецкая Э.Ф. Фармакологическая регуляция психических процессов. — М., 1985.—156 с.
  10. 10. Лапин И.П. Фармакологические различия между кинурениновыми и коразоловымисудорогами (участие ГАМК-Б-рецепторов и дофамина) // Эксперим. и клин. фар-макология. — 1998. — 61, № 2. — С. 20-22.
  11. Мелдрум Б. Нейромедиаторы и эпилепсия В кн. Нейротрансмиттерные системы /Под ред. Н. Дж. Легга. — М.: Медицина, 1982. — С. 164-179.
  12. Bassareo V., Tanda G., Petromilli P., Giua C., Di Chiara G. Non-psychostimulantdrugs of abuse and anxiogenic drugs activate with differential selectivity dopaminetransmission in the nucleus accumbens and in the medial prefrontal cortex of the rat // Psychopharmacology (Berl). — 1996. — 124, № 4. — С. 293-299.
  13. Bloom P., Madeja M., Mushhoff U., Specmann E.-J. Effects of pentylenetetrazole onGABA receptors expressed in oocytes of Xenopus laervus: extra- and intracellular sitesof action // Neurosci. Let. — 1996. — 205. — P. 115-118.
  14. Carlton S.M., Zhou S., Coggeshall R.E. Peripheral GABA(A) receptors: evidence forperipheral primary afferent depolarization // Neuroscience. — 1999. — 93, № 2. —Р. 713-722.
  15. Danysz W., Parsons C.G. Glycine and N-methyl-D-aspartate receptors: physiologicalsignificance and possible therapeutic applications // Pharmacol. Rew. — 1998. — 50,№ 4. — Р. 597-664.
  16. Davidoff R.A., Hackman J.C. Pentylenetetrazol and reflex activity of isolated frogspinal cord // Neurology. — 1978. — 28, № 5. — Р. 488-494.
  17. De Roeck J., van Bockstaele M., De Potter W.P. The effect of pentylenetetrazol onthe levels of dopamine-beta-hydroxylase in the cerebrospinal fluid of rabbits: a dose-dependent relationship // Neurosci Lett. — 1983. — 35, № 1. — Р. 65-70.
  18. De Souza M.M., Schenberg L.C., de Padua Carobrez A. NMDA-coupled periaqueductalgray glycine receptors modulate anxioselective drug effects on plus-maze performance// Behav Brain Res. — 1998. — 90, № 2. — Р. 157-165.
  19. 19. File S.E., Curle P.F., Baldwin H.A., Neal M.J. Anxiety in the rat is associated withdecreased release of 5-HT and glycine from the hippocampus // Neurosci Lett. —1987. — 83, № 3. — Р. 318-322.
  20. 20. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA receptorsexpressed in Xenopus oocytes // Science. — 1988. — 214. — Р. 835-837.
  21. Lippa A.S., Nash P.A., Greenblatt E.N. Pre-clinical neuropsychopharmacological testingprocedures for anxiolytic drugs // Pharmacology (Anxiolytics). — 1979. — 3. —Р. 41-66.
  22. Macdonald R.L., Olsen R.W. GABA-A receptor channels // Annual Rew. Neurosci.— 1994. — 17. — Р. 569-602.
  23. Maksay G., Simonyi M. Kinetic regulation of convulsant (TBPS) binding by GABAergicagents // Mol. Pharmacol. — 1986. — 30. — Р. 321-328.
  24. Matheus M.G., Nogueira R.L., Carobrez A.P. et al. Anxiolitic effect of glycineantagonists microinjected into the dorsal periaqueductal grey // Psychopharmaco-logy. — 1994. — 113. — Р. 565-569.
  25. Matsubara M., Suzuki S., Miura K.et al. A study of the effects of antidepressants onthe GABAA receptor and its complex based on the drug actions on the power-spectralchanges of rat hippocampal EEG induced by GABA antagonists and inverse agonists// Nihon Shinkei Seishin Yakurigaku Zasshi. — 1997. — 17, № 2. — Р. 75-83.
  26. Miller J.W., Gray B.C., Bardgett M.E. Characterization of cholinergic regulation ofseizures by the midline thalamus // Neuropharmacology. — 1992. — 31, № 4, —Р. 349-356.
  27. Nichols A.C., Yielding K.L. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenicacid derivatives that are antagonists at the NMDA-associated glycine binding site //Mol. Chem. Neuropathol. — 1998. — 35, № 1-3. — Р. 1-12.
  28. Nutt D.J. The pharmacology of human anxiety // Pharmacological therapy. — 1990. —47. — Р. 233-266.
  29. 29. Ogren S.O., Pakh B. Effects of dopamine D1 and D2 receptor agonists and antagonistson seizures induced by chemoconvulsants in mice // Pharmacol. Toxicol. — 1993. —72, № 4-5. — Р. 213-220.
  30. 30. Ramanyaneyulu R., Ticku M.K. Interactions of pentamethylenetetrazole and tetrazoleanalogues with the picrotoxin site of benzodiazepine-GABA receptor-ionophore complex// Eur. J. Pharmacol. — 1984. — 98. — Р. 337-345.
  31. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysisof the effects of putative “anxiogenic” agens in the mouse elevated plus-maze //Pharmacology, Biochemistry and Bihavior. — 1995. — 3. — Р. 1-9.
  32. Serra M., Dazzi L., Cagetti E. et al. Effect of pentylenetetrazole-induced kindling onacetylcholine release in the hippocampus of freely moving rats // J. Neurochem. —1997. — 68, № 1. — Р. 313-318.
  33. Simon P., Panissaud C., Costentin J. Anxiogenic-like effects induced by stimulation ofdopamine receptors // Pharmacol. Biochem. Behav. — 1993. — 45, № 3. — Р. 685-690.
  34. Szot P., White S.S., Veith R.C. Effect of pentylenetetrazol on the expression oftyrosine hydroxylase mRNA and norepinephrine and dopamine transporter mRNA //Brain. Res. Mol. Brain Res. — 1997. — 44, № 1. — Р. 46-54.
  35. Upton N., Stean T., Middlemiss D., Blackburn T., Kennett G. Studies of the role of5-HT2C and 5-HT2B receptors in regulating generalised seizure threshold in rodents//Eur. J. Pharmacol. — 1998. — 359, № 1. — Р. 33-40.
  36. Wallis C.J., Lal H. A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine(mCPP) as a putative animal model of anxiety // Prog Neuropsychopharmacol. Biol.Psychiatry. — 1998. — 22, № 3. — Р. 547-565.
  37. Yoon K.W., Covey D.F., Rothmans S.M. Multiple mechanisms of picrotoxin block ofGABA-induced currents in rats hippocampal neurons // J. Physiol. — 1993. — 464.—Р. 423-439.
  38. Zhu Y.S., Inturrisi C.E. Metrazole induction of c-fos and proenkephalin gene expressionin the rat adrenal and hippocampus: pharmacological characterization // Brain Res.Mol. Brain Res. — 1993. — 20, № 1-2. — Р. 118-124.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2018.